No abstract available.
Dentigerous Cyst*

No abstract available.
Rickets*

No abstract available.
Democratic People's Republic of Korea* ; Health Services*

The pharmacological therapy of cardiac arrhythmias is still challenging. As is well known, antiarrhythmic drugs have a narrow therapeutic-toxic window and can induce lethal proarrhythmia (antiarrhythmic drug-induced arrhythmia). The harmful effect of antiarrhythmic drug was proven by CAST and so many clinical trials. Thus we need strict indications for prescription and objective parameters for monitoring of the drug action and side effects. The cardiac arrhythmias are classified as ectopic beats, bradyarrhythmia, and tachyarrhythmia. The main target of antiarrhythmic drugs is tachyarrhythmia. The clinical role of antiarrhythmic drugs is the acute conversion of arrhythmia to sinus rhythm and the chronic suppression/prevention of tachycardia. The cardiac arrhythmia (arrhythmogenesis) occurs in harmony of 3 components, namely, substrate, precipitating (modulating) factors, and trigger. The acute modification of arrhythmogenic environment by drug may be efficient, but the chronic suppression of arrhythmia only by the drug may not be complete. Recently, the clinical role of chronic drug therapy is replaced by RFCA (in patients with SVT except atrial fibrillation) and ICD (VT/SCD). The antiarrhythmic drugs are usually classified into Class I (sodium channel blocker), Class II (beta-blocker), Class III (potassium channel blocker), Class IV (calcium channel blocker), and others (digoxin and adenosine), according to Vaughn-Williams suggestion. Nowadays, the clinical electrophysiologist reclassified the agents into calcium channel-dependent drug (Class II, IV, digoxin, and adenosine) and sodium/potassium channel-dependent drug (Class I and III). The drug is effective only when the concentration in blood or tissue is sufficient to modify the arrhythmogenic substrate. We need to know the pharmacokinetic and pharmacodynamic properties of antiarrhythmic drugs exactly. We can expect the blood concentration of a drug if we know the elimination half-life and the dosing schedule of the drug because most drugs (including antiarrhythmic agents) have the first-order (elimination) kinetic. For a new steady-state of drug concentration, we should wait for 3 to 4 times of the half-life after changing the dosage (prescription). Finally, the consideration and management of the underlying heart disease and precipitating/modulating factors are needed for the effective antiarrhythmic drug therapy.
Anti-Arrhythmia Agents ; Appointments and Schedules ; Arrhythmias, Cardiac ; Bradycardia ; Calcium ; Digoxin ; Drug Therapy ; Half-Life ; Heart Diseases ; Humans ; Prescriptions ; Tachycardia

No abstract available.
Ghrelin* ; Prader-Willi Syndrome*

No abstract available.
Ghrelin* ; Prader-Willi Syndrome*

No abstract available.
Adrenal Hyperplasia, Congenital* ; Genetic Association Studies*

Objective To analyse the therapeutic effect of Carvedilol in patients with severe heart failure.Methods The clinical data of 89 Carvedilol patients treated with dilated cardiomyopathy were retrospective analysis.Results The overall therapeutic effective rate was 98.88％,because of one death related to discontinued use of medication.Before and after treatment,systolic left ventricular cavity diameter (LVDD) were (68.25 ± 2.15) mm,(56.89 ±4.21) mm,respectively,and left ventricular ejection fraction(LVEF) were (28.63 ±0.33)％,(40.56 ±3.98) ％,respectively,there were significantly differences (t =7.215,16.877,all P ＜ 0.05).Conclusion Carvedilol is the cornerstone in the drug treatments of patients with dilated cardiomyopathy.

Objective To evaluate the impact of hypertension self-management on self efficacy of community residents.Methods November 2011 to February 2012,twenty-eight medium-sized and better adherence to community was selected from fourteen districts and counties in Beijing.In this community-based randomized controlled trial,323 hypertensive patients were randomly assigned to the treatment group (n =159,receiving hypertension self-management) and the control group (n=164,receiving standard hypertension management).A questionary survey was completed at baseline and 6 weeks.Rank sum test or Chi-square test was used for data analysis.Results The average age of the treatment group or the control group was (61.9 ±9.1) vs (61.8 ±9.0) years old,respectively.No significant difference in mean age,gender and education level was found between the two groups (F =0.164,x2 values were 0.782 and 2.093,respectively ; all P ＞ 0.05).In the treatment group,the scores of fatigue,headache and shortness of breath were declined (when compared with the controlled females,Z =-5.198,-3.873,-2.781 ; P ＜ 0.05).Self-efficacy score of the treatment group was increased after the intervention.Women's symptom management self-efficacy and common disease management self-efficacy were significantly higher (Z=-2.958,-2.582; P ＜ 0.05).In comparison with the control group,before and after self-management,the added scores of communication ability with doctors were increased.But the difference was not statistically significant (P ＞ 0.05).Conclusion Six-week self-management program may improve self efficacy among hypertensive patients.

Objective To explore the expression of cathepsin L in hepatocellular carcinoma and to analyze its relationship with clinical and pathological features. Methods Fifty-eight specimens of hepatocellular carcinoma were studied, including 18 well-differentiated, 18 moderately differentiated and 22 poorly differentiated. Classified by TNM clinical stage, 26 were in Ⅰ/Ⅱ stage and 32 in Ⅲ/Ⅳ stage. The expressions of cathepsin L were detected with immunohistochemistry and RT-PCR. Their relationship with the clinical and pathological features of hepatocellular carcinoma was analyzed. Results The positive rate of cathepsin L protein was 72.4% (42/58), and the expressions of cathepsin L protein were significantly different among the specimens of pathological grades of tumor, of TNM clinical stages and with/without metastasis. The positive rate of cathepsin L mRNA was 65.5% (38/58). The expression of cathepsin L mRNA in hepatocellular carcinoma was correlated with pathological grades of tumor, TNM clinical stages and lymph node metastasis. Conclusion Cathepsin L plays an important role in the occurrence of hepatocellular carcinoma for its correlation with infiltration and metastasis of hepatocellular carcinoma. Cathepsin L can be used as a useful marker for the prognosis of hepatocellular carcinoma patients.